Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/49333| Title: | Innovative therapeutic cancer vaccine PDC*lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer | Authors: | Vansteenkiste, J Demedts, I CUPPENS, Kristof Pons-Tostivint, E Wauters , E Borm, FJ Sibille, A Colinet, B Pérol, M Theelen, WSME Biesma, B van de Kerkhove, C Buchmeier, E Althoff, FC Derijcke, S Moro-Sibilot, D Laulagnier, K Halioua, E Levy, L Genin, M Michel, S Dedry, C Duchayne, C Collodoro, M Renard, F Adriaenssens, S De Vos , B Cantero, F Plumas, J Skrzypski, M |
Issue Date: | 2025 | Publisher: | ELSEVIER | Source: | ESMO open, 10 (11) (Art N° 105844) | Abstract: | While immune checkpoint inhibitors have revolutionized the treatment of non-small-cell lung cancer (NSCLC), many patients still suffer from either primary or acquired treatment resistance. Stimulation of antitumor cellular immunity with a therapeutic cancer vaccine in combination with anti-programmed cell death (ligand) protein 1 [PD-(L)1] may improve outcome. PDC∗lung01 is a cancer vaccine made of irradiated plasmacytoid dendritic cells loaded with six NSCLC tumor antigens (NY-ESO-1, MAGE-A3, MAGE-A4, Multi-MAGE-A, MUC1, and Survivin), and available as a ready-to-use product. | Keywords: | therapeutic cancer vaccine;plasmacytoid dendritic cells;immune checkpoint inhibitor;non-small-cell lung cancer;clinical trials phase I/II | Document URI: | http://hdl.handle.net/1942/49333 | e-ISSN: | 2059-7029 | DOI: | 10.1016/j.esmoop.2025.105844 | ISI #: | 001599984300001 | Rights: | 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.